Select a year:
Select a category:

4Moving Biotech received the Seal of Excellence from the European Commission

4Moving Biotech, our spin-off company centered on 4P004, received the Seal of Excellence from the European Commission, for its application submitted to the Horizon 2020 Accelerator (SME instrument). This award is related to the development of 4P004, our disease modifier treatment for osteoarthritis. The Seal of Excellence is a high-quality label awarded by a panel&hellip

Read More

Institut de la Vision & 4P-Pharma announce a partnership for the development of an innovative therapy for retinal diseases

4P-Pharma, a clinical-stage biotechnology company and the research center Institut de la Vision (Sorbonne Université, Inserm, CNRS) establish a partnership agreement for the development of 4P020, a promising therapeutic approach for dry age-related macular degeneration (dAMD) and Stargardt disease with the support of the SATT Lutech. This drug candidate, initially studied by Dr Valerie Fontaine at the Institut de la Vision, opens&hellip

Read More

4P-Pharma at the Biotech Showcase 2021 online

Our chairwoman, Revital Rattenbach, will attend the Biotech Showcase, January 11th – 15th online. Contact us via the partnering platform or by e-mail to schedule a virtual meeting and discuss collaboration opportunities. For more information : https://informaconnect.com/biotech-showcase/

Read More

Happy New Year 2021 !

The entire 4P-Pharma team wishes you a happy 2021 ! May this new year be a source of achievement and joy for you and your loved ones Design by Valérie Baudry

Read More

4P-Pharma will give a talk during the DDIP 2020

4P-Pharma’s CSO, Patrice Denèfle, will give a talk on 4P004 : « Accelerating therapeutic innovation for patient through drug repurposing : a use case in Osteoarthritis » at the Drug Discovery Innovation Programme (DDIP) virtual meeting organized by the World BI, on November, 17th 2020, 10:00 a.m CET. To learn more about 4P-Pharma, our pipeline&hellip

Read More

4P-Pharma will present 4P004 data at ACR Convergence 2020

Pr. Francis Berenbaum (Head of Rheumatology at Saint-Antoine Hospital, and Professor of Rheumatology at Sorbonne University, in Paris, France) will present a poster on 4P004 entitled “Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect” (#0703) during the ACR Convergence 2020 annual meeting, November&hellip

Read More